Outcomes of Pembrolizumab plus chemotherapy for patients with metastatic non-squamous NSCLC: Real-world evidence
Background Pembrolizumab with chemotherapy (immunochemotherapy) has shown encouraging overall survival (OS) benefits in non-squamous mNSCLC, as demonstrated by the KEYNOTE-189 trial. However, randomised controlled trials may not fully capture the diversity of real-world patients. This study aims to...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis
2025-12-01
|
| Series: | Pulmonology |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/25310429.2025.2457856 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|